- Home
- FluxMPS™ Dulbecco's Modified Eagle Medium (DMEM), Low Glucose w/o Sodium Pyruvate, Sodium Bicarbonate: 1X Liquid
FluxMPS™ Dulbecco's Modified Eagle Medium (DMEM), Low Glucose w/o Sodium Pyruvate, Sodium Bicarbonate: 1X Liquid
FluxMPS™ DCP-DMEML-PB1X is a Microfluidics Suitable, quadruple-stage ultra-filtered (0.1 µm ×2 + 0.04 µm ×2) DMEM Low Glucose formulation engineered for microphysiological systems (MPS), organ-on-a-chip (OoC), and microfluidic tissue models. Processed through a validated four-stage filtration train reaching a 0.04 µm final polish, it supports unobstructed microchannel flow, 0.1 µm mycoplasma-retentive filtration, and low-background optical measurements. Formulation: [+] Low Glucose, [+] L-Glutamine, [+] Phenol Red, [+] Calcium, [+] Magnesium | [-] Sodium Pyruvate, [-] Sodium Bicarbonate.
- Quadruple-stage filtration train: 0.1 µm Prefiltration I → 0.04 µm Final filtration I → 0.1 µm Prefiltration II → 0.04 µm Final filtration II, reaching a 0.04 µm final cut-off
- Low Glucose (1.0 g/L) base formulated without sodium pyruvate and without sodium bicarbonate — suited to CO₂-independent or user-buffered microfluidic culture
- Endotoxin release specification: < 0.05 EU/mL (LAL, USP <85>), tested per manufacturing batch prior to release
- Contains phenol red (15.900 mg/L) as a visual pH indicator — this is not a phenol red–free formulation
- 4× Basal Medium Eagle (BME) amino acid and vitamin concentrations across 31 total ingredients
- Manufactured under an ISO 13485:2016 quality management system with per-lot Certificate of Analysis
- Custom pH, glucose concentration, salts, and nutrient adjustments available on request
- Glucose1000 mg/L (1.0 g/L, Low Glucose)
- L-Glutamine584 mg/L
- Sodium PyruvateNot included
- Sodium BicarbonateNot included
- Phenol Red15.900 mg/L
- pH (USP <791>)7.4
- Osmolality (USP <785>)310–350 mOsm/kg H2O
- Endotoxin (USP <85>)< 0.05 EU/mL
- Filtration0.1 µm ×2 + 0.04 µm ×2
- Storage / Shelf Life2–8°C, protect from light / 12 months from date of manufacture, unopened
Engineered where standard media fails
Conventional 0.22 µm–filtered DMEM passes mycoplasma (0.2–0.3 µm diameter), subvisible particulates, and endotoxin fragments that accumulate inside microfluidic channels, clog chip geometries, and corrupt sensor readings and metabolic signals. FluxMPS™ was designed specifically for these failure modes.
Microchannel-safe purity
0.04 µm final filtration removes sub-micron particles that clog channels below 100 µm. USP <788> Method 1 (light obscuration) particulate compliance supports safe perfusion in fine chip geometries.
Total metabolic control
Low glucose (1.0 g/L) base supplied without sodium pyruvate and without sodium bicarbonate lets researchers define the carbon source and buffer system precisely for Warburg-effect and metabolic flux studies.
Ultrapure-grade water
Every batch is prepared using Ultrapure Type 1 water (18.2 MΩ·cm), supporting low trace-metal and organic-carbon background in the finished medium.
Low background for imaging
Ultra-low particulate count and (in phenol red–free variants) no autofluorescent dye delivers a cleaner particulate baseline for confocal, widefield, and biosensor measurements on chip.
Rich, stable nutrient profile
4× BME amino acid & vitamin concentrations, micro-batch manufacturing, and lot-to-lot QC support reproducible cell growth across multi-day perfusion experiments.
Customization on demand
pH, glucose concentration, salts, HEPES, and nutrient composition are adjustable per your protocol. Contact support@diagnocine.com to specify your formulation.
Quadruple-stage filtration system
A validated quadruple-stage filtration train reaching a final 0.04 µm polish, engineered to exclude sub-mycoplasma particulates from microfluidic channels while preserving full nutrient integrity.
-
1
0.1 µm Prefiltration I
Removes large aggregates, cell debris, and contaminants; protects the first 0.04 µm final filter and extends its service life.
-
2
0.04 µm Final filtration I
First 0.04 µm pass; retains sub-micron particulates and microaggregates that a 0.22 µm filter does not.
-
3
0.1 µm Prefiltration II
A second, dedicated 0.1 µm prefilter protecting the second 0.04 µm cartridge — the pairing runs in series, not as a single descending cascade.
-
4
0.04 µm Final filtration II — Polish
Ultimate polishing filter ahead of aseptic fill & finish, completing the quadruple-stage purity architecture.
Performance vs. conventional media
FluxMPS™ DCP-DMEML-PB1X is processed to a materially finer specification than standard 0.22 µm–filtered DMEM, addressing microchannel fouling and particulate-driven signal noise in sensitive MPS workflows.
passes (0.1 µm ×2 +
0.04 µm ×2)
pore size — sub-mycoplasma
polishing
© Diagnocine® — DCP-DMEML-PB1X
Designed for next-generation cell models
FluxMPS™ DCP-DMEML-PB1X supports demanding cell culture platforms — from single-channel microfluidic chips to multi-organ body-on-a-chip systems — where media purity, metabolic precision, and optical clarity matter.
Automated Bioreactors & Robotics
An optional 0.01 µm (10 nm) MPS Grade variant is available on request for automated bioreactor perfusion systems, robotic liquid handlers, and long-duration closed-loop platforms where even trace particulates cause valve failure or sensor drift.
- Total Particulate Exclusion: 10 nm filtration removes nanoparticulate aggregates invisible to standard QC methods
- Valve & Sensor Protection: Reduces micro-fouling of solenoid valves, peristaltic pump tubing, and inline optical sensors
- Extended Perfusion Stability: Consistent nutrient delivery over weeks-long culture without filter replacement in the chip circuit
Inquiry Required: The 0.01 µm MPS Grade variant is a custom product. Contact support@diagnocine.com to request it for your automated system.
Micro Physiological System (MPS) & Chip
0.04 µm–filtered media supports laminar flow fidelity and helps avoid microchannel clogging in complex multi-organ chip architectures.
Warburg Effect & Metabolic Research
Low glucose (1.0 g/L) base without sodium pyruvate enables precise control of aerobic glycolysis, supporting Warburg phenotype studies.
iPSC-Derived Models
Ultra-low endotoxin (< 0.05 EU/mL release specification) and 0.1 µm mycoplasma-retentive filtration support sensitive iPSC-differentiation protocols.
Endothelial & Primary Cells
Particle-controlled, endotoxin-tested DMEM supports HUVEC and primary hepatocyte monolayer integrity, useful for barrier-function assays and TEER monitoring.
Metabolic Flux Analysis
Defined low-glucose formulation without sodium pyruvate provides a clean metabolic background for ¹³C isotope tracing and extracellular flux measurement. Not compatible with Agilent Seahorse XF assays, which require bicarbonate-free, phenol red-free medium — this formulation contains phenol red.
Microscopy & Optical Sensing
Ultra-low particulate count delivers a cleaner particulate baseline for confocal imaging, biosensor arrays, and TEER measurements on chip.
Analytical release specifications
Every lot is released against the full specification matrix below. CoA available on request: support@diagnocine.com.
| Parameter | Specification |
|---|---|
| Formulation | [+] Low Glucose, [+] L-Glutamine, [+] Phenol Red, [+] Calcium, [+] Magnesium | [-] Sodium Pyruvate, [-] Sodium Bicarbonate |
| Appearance | Orange-colored, clear solution |
| pH USP <791> | 7.4 |
| Osmolality USP <785> | 310–350 mOsm/kg H2O |
| Glucose | 1000 mg/L (1.0 g/L, Low Glucose) |
| L-Glutamine | 584 mg/L |
| Sodium Pyruvate | Not included |
| Phenol Red | 15.900 mg/L |
| Parameter | Specification |
|---|---|
| Endotoxin USP <85> BET | < 0.05 EU/mL |
| Sterility USP <71> | No growth / 14 days |
| Mycoplasma | 0.1 µm mycoplasma-retentive filtration (not tested per lot) |
| Particulate ≥10 µm USP <788> Method 1 | NMT 25/mL |
| Particulate ≥25 µm USP <788> Method 1 | NMT 3/mL |
| Water purity | Type 1, 18.2 MΩ·cm |
| Manufacturing std. | ISO 13485:2016 |
| Fill environment | ISO Class 5 (Class 100) |
| Parameter | Specification |
|---|---|
| Storage temperature | 2–8°C, away from light |
| Freeze-thaw | Do not freeze |
| Shelf life | 12 months from date of manufacture, unopened |
| Shipping condition | Cold pack |
| CO2 requirement | Not required — bicarbonate-free formulation; use HEPES or an equivalent buffer for CO2-independent culture |
| Parameter | Specification |
|---|---|
| Raw material grade | Reagent / cell culture grade |
| Traceability | Full lot traceability per ISO 13485 |
| Manufacturing QMS ISO | ISO 13485:2016 certified |
| UNSPSC | 41116155 — Molecular biology and cell culture growth media (UNv260801) |
| Regulatory alignment | 21 CFR Part 820 (QMSR) aligned |
| Production method | Micro-batch, per-lot QC release |
| Intended use | Research Use Only (RUO) |
Full composition (mg/L)
FluxMPS™ DMEM is a modification of Basal Medium Eagle (BME) containing 4× BME concentrations of amino acids and vitamins, plus glycine, serine, and ferric nitrate. Total ingredients: 31. Every ingredient listed below is present in the released product; CAS numbers provided for traceability.
| Component | CAS Number | mg/L |
|---|---|---|
| INORGANIC SALTS | ||
| Calcium chloride dihydrate | 10035-04-8 | 265.000 |
| Ferric nitrate nonahydrate | 7782-61-8 | 0.100 |
| Magnesium sulfate anhydrous | 7487-88-9 | 97.720 |
| Potassium chloride | 7447-40-7 | 400.000 |
| Sodium chloride | 7647-14-5 | 6400.000 |
| Sodium dihydrogen phosphate anhydrous | 7558-80-7 | 109.000 |
| Component | CAS Number | mg/L |
|---|---|---|
| AMINO ACIDS | ||
| Glycine | 56-40-6 | 30.000 |
| L-Arginine hydrochloride | 1119-34-2 | 84.000 |
| L-Cystine dihydrochloride | 30925-07-6 | 62.570 |
| L-Glutamine | 56-85-9 | 584.000 |
| L-Histidine hydrochloride monohydrate | 5934-29-2 | 42.000 |
| L-Isoleucine | 73-32-5 | 105.000 |
| L-Leucine | 61-90-5 | 105.000 |
| L-Lysine hydrochloride | 657-27-2 | 146.000 |
| L-Methionine | 63-68-3 | 30.000 |
| L-Phenylalanine | 63-91-2 | 66.000 |
| L-Serine | 56-45-1 | 42.000 |
| L-Threonine | 72-19-5 | 95.000 |
| L-Tryptophan | 73-22-3 | 16.000 |
| L-Tyrosine Disodium Salt dihydrate | 69847-15-0 | 103.790 |
| L-Valine | 72-18-4 | 94.000 |
| Component | CAS Number | mg/L |
|---|---|---|
| VITAMINS | ||
| Choline chloride | 67-48-1 | 4.000 |
| D-Ca-Pantothenate | 137-08-6 | 4.000 |
| Folic acid | 59-30-3 | 4.000 |
| Nicotinamide | 98-92-0 | 4.000 |
| Pyridoxal hydrochloride | 65-22-5 | 4.000 |
| Riboflavin | 83-88-5 | 0.400 |
| Thiamine hydrochloride | 67-03-8 | 4.000 |
| i-Inositol | 87-89-8 | 7.200 |
| OTHERS | ||
| D-Glucose | 50-99-7 | 1000.000 |
| Phenol red sodium salt | 34487-61-1 | 15.900 |
Manufacturing & compliance
Every FluxMPS™ product is manufactured and released under a multi-layer quality system spanning raw materials, in-process controls, and final-product testing.
ISO 13485:2016 Quality Management
Manufactured under ISO 13485:2016-certified facilities. All final packaging, QA, and testing are conducted at the Diagnocine R&D and Quality Testing Center, Totowa, NJ, USA.
Ultrapure Type 1 Water
All formulations use Ultrapure Type 1 water (18.2 MΩ·cm) to minimize trace-metal and organic-carbon background across every batch.
ISO Class 5 Fill & Finish
Final aseptic fill performed in validated ISO Class 5 (Class 100) laminar-flow workstations, supporting container-closure integrity at the point of fill.
Micro-Batch Precision
Small-batch production with full per-lot traceability. Each batch is individually tested and released — no blending of lots, no averaging of QC results. A Certificate of Analysis is issued for every batch.
- Endotoxin — LAL assay, USP <85> Bacterial Endotoxins Test; assay sensitivity 0.005 EU/mL; release specification < 0.05 EU/mL
- pH, osmolality, conductivity, appearance and clarity
- Sterility
Endotoxin — USP <85> BET
LAL assay. Release specification: < 0.05 EU/mL. Every manufacturing batch is tested prior to release.
Particulate — USP <788> Method 1
Light obscuration particle count. Release limits: NMT 25/mL (≥10 µm) and NMT 3/mL (≥25 µm).
Osmolality — USP <785>
Freezing-point osmometry. Target range: 310–350 mOsm/kg H2O.
Documentation & CoA
Full Certificate of Analysis with raw-material traceability, in-process records, and final-release test results available for every batch upon request.
How DCP-DMEML-PB1X compares
FluxMPS™ DCP-DMEML-PB1X vs. conventional 0.22 µm–filtered DMEM formulations.
| Parameter | DCP-DMEML-PB1X (FluxMPS™) | Conventional DMEM (0.22 µm filtered) |
Standard Alt. DMEM (0.22 µm filtered) |
|---|---|---|---|
| Grade | Microfluidics Suitable (0.04 µm) | Standard grade | Standard grade |
| No sodium pyruvate, no sodium bicarbonate — supports CO2-independent systems with a researcher-defined carbon source | check_circle Yes | cancel No | cancel No |
| Final filtration pore size | 0.04 µm | 0.22 µm | 0.22 µm |
| Number of filtration stages | 4 (Quadruple) | 1 | 1 |
| Mycoplasma-retentive filtration | check_circle Yes (0.1 µm) | cancel No | cancel No |
| Endotoxin (release specification) | < 0.05 EU/mL | Corning classical liquid media — < 0.25 EU/mL Sigma-Aldrich DMEM complete medium — ≤ 2 EU/mL Gibco classical DMEM — Not specified (recorded per lot) |
|
| USP particulate compliance | check_circle USP <788> Method 1 | cancel Not tested | cancel Not tested |
| Water quality | Type 1, 18.2 MΩ·cm | Purified water | Purified water |
| Manufacturing QMS | ISO 13485:2016 | ISO 9001 or none | ISO 9001 or none |
| Microfluidic channel compatibility | check_circle Microfluidics Suitable | cancel Risk of clogging | cancel Risk of clogging |
| Custom formulation | check_circle Available | cancel Fixed formulation | cancel Fixed formulation |
Comparison figures from published supplier specifications, accessed 2026-09-02. Suppliers that publish no numeric endotoxin specification are shown as "Not specified".
Frequently asked questions
Common questions about FluxMPS™ DCP-DMEML-PB1X and Microfluidics Suitable DMEM formulations.
Supporting literature
Key peer-reviewed publications supporting Microfluidics Suitable, ultra-filtered media in organ-on-a-chip, microfluidic, and metabolic research applications.
- Huh D, et al. Reconstituting organ-level lung functions on a chip. Science. 2010;328:1662–1668. doi:10.1126/science.1188302
- Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nat Biotechnol. 2014;32:760–772. doi:10.1038/nbt.2989
- Warburg O. On the origin of cancer cells. Science. 1956;123:309–314. doi:10.1126/science.123.3191.309
- Novak R, et al. Robotic fluidic coupling and interrogation of multiple vascularized organ chips. Nat Biomed Eng. 2020;4:407–420. doi:10.1038/s41551-019-0497-x
- Katt ME, et al. In vitro tumor models: advantages, disadvantages, variables, and selecting the right platform. Front Bioeng Biotechnol. 2016;4:12. doi:10.3389/fbioe.2016.00012
- Campisi M, et al. 3D self-organized microvascular model of the human blood-brain barrier. Biomaterials. 2018;180:117–129. doi:10.1016/j.biomaterials.2018.07.014
- Jang KJ, et al. Human kidney proximal tubule-on-a-chip for drug transport and nephrotoxicity assessment. Integr Biol. 2013;5:1119–1129. doi:10.1039/c3ib40049b
- Schimek K, et al. Integrating biological vasculature into a multi-organ-chip microsystem. Lab Chip. 2013;13:3588–3598. doi:10.1039/c3lc50217a
- Luni C, et al. High-efficiency cellular reprogramming with microfluidics. Nat Methods. 2016;13:446–452. doi:10.1038/nmeth.3832
- Sung JH, et al. Microfabricated mammalian organ systems and their integration into models of whole animals and humans. Lab Chip. 2013;13:1201–1212. doi:10.1039/c3lc41017j


